This paper by Dr. Agneta Wikman, Professor at Karolinska University Hospital explores an approach that uses non-invasive prenatal testing to determine the fetal RHD status, allowing targeted administration of antenatal anti-D prophylaxis only to those who will benefit from it. Learn more about the current strategies of fetal RHD and the experiences and considerations surrounding planning a fetal RHD screening program.
Current strategies of fetal RHD screening.
Requirements in clinical routine testing.
Planning a fetal RHD screening program.
Get access to the paper by filling out the form below
